The core team of the company comes from Peking
University, Tsinghua University, Harvard University, University of
California, Berkeley and other famous universities
or research institutions at home and abroad.
Founded in 2021, the company is dedicated to providing scale-up, low-cost stem cell therapy solutions for a range of major degenerative diseases for which no clinical solutions exist.
Patients first, "Blade" second, shareholders third.
In May 2021, XellSmart Bio officially announced the establishment.
In November 2023, XellSmart Biomedical (Suzhou) Co., Ltd. (XellSmart Bio)'s clinical-grade iPSC-derived subtype-specific neural precursor cell product to treat ALS (amyotrophic lateral sclerosis) was granted Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA).
This is the worldwide first iPS-derived cell therapeutic medicine from China Granted by the FDA and granted orphan drug designation, and is also the worldwide first iPS-derived cell therapeutic medicine with global Orphan Drug Designation for the treatment of ALS to date.
COPYRIGHTⓒ 2021
